;PMID: 8555071 ;source_file_1310.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..35] = [t:0..35] ;1)sentence:[e:40..132] = [t:40..132] ;2)section:[e:136..213] = [t:136..213] ;3)section:[e:217..272] = [t:217..272] ;4)sentence:[e:276..351] = [t:276..351] ;5)sentence:[e:352..553] = [t:352..553] ;6)sentence:[e:554..758] = [t:554..758] ;7)sentence:[e:759..876] = [t:759..876] ;8)sentence:[e:877..982] = [t:877..982] ;9)section:[e:986..1030] = [t:986..1030] ;section 0 Span:0..35 ;Br J Haematol 1995 Nov;91(3):661-3 (SEC (FRAG (NNP:[0..2] Br) (NNP:[3..4] J) (NNP:[5..13] Haematol) (CD:[15..19] 1995) (IN:[20..27] Nov;91-LRB-) (CD:[27..28] 3) (-RRB-:[28..29] -RRB-) (::[29..30] :) (CD:[30..35] 661-3))) ;sentence 1 Span:40..132 ;c-kit point mutation of extracellular domain in patients with ;myeloproliferative disorders. ;[40..45]:gene-rna:"c-kit" ;[46..60]:variation-type:"point mutation" ;[102..131]:malignancy-type:"myeloproliferative disorders" (SENT (NP-HLN (NP (NN:[40..45] c-kit) (NN:[46..51] point) (NN:[52..60] mutation)) (PP (IN:[61..63] of) (NP (JJ:[64..77] extracellular) (NN:[78..84] domain))) (PP-LOC (IN:[85..87] in) (NP (NP (NNS:[88..96] patients)) (PP (IN:[97..101] with) (NP (JJ:[102..120] myeloproliferative) (NNS:[122..131] disorders))))) (.:[131..132] .))) ;section 2 Span:136..213 ;Nakata Y, Kimura A, Katoh O, Kawaishi K, Hyodo H, Abe K, Kuramoto A, Satow ;Y. (SEC (FRAG (NNP:[136..142] Nakata) (NNP:[143..144] Y) (,:[144..145] ,) (NNP:[146..152] Kimura) (NNP:[153..154] A) (,:[154..155] ,) (NNP:[156..161] Katoh) (NNP:[162..163] O) (,:[163..164] ,) (NNP:[165..173] Kawaishi) (NNP:[174..176] K,) (NNP:[177..182] Hyodo) (NNP:[183..185] H,) (NNP:[186..189] Abe) (NNP:[190..192] K,) (NNP:[193..201] Kuramoto) (NNP:[202..203] A) (,:[203..204] ,) (NNP:[205..210] Satow) (NNP:[211..212] Y) (.:[212..213] .))) ;section 3 Span:217..272 ;Department of Environment, Hiroshima University, Japan. (SEC (FRAG (NNP:[217..227] Department) (IN:[228..230] of) (NNP:[231..242] Environment) (IN:[242..243] ,) (NNP:[244..253] Hiroshima) (NNP:[254..264] University) (IN:[264..265] ,) (NNP:[266..271] Japan) (.:[271..272] .))) ;sentence 4 Span:276..351 ;c-kit is a tyrosine kinase receptor whose ligand is stem cell factor (SCF). ;[276..281]:gene-protein:"c-kit" ;[287..311]:gene-protein:"tyrosine kinase receptor" ;[328..344]:gene-protein:"stem cell factor" ;[346..349]:gene-protein:"SCF" (SENT (S (NP-SBJ (NN:[276..281] c-kit)) (VP (VBZ:[282..284] is) (NP-PRD (NP (DT:[285..286] a) (NN:[287..295] tyrosine) (NN:[296..302] kinase) (NN:[303..311] receptor)) (SBAR (WHNP-1 (WP$:[312..317] whose) (NN:[318..324] ligand)) (S (NP-SBJ-1 (-NONE-:[324..324] *T*)) (VP (VBZ:[325..327] is) (NP-PRD (NP (NML (NN:[328..332] stem) (NN:[333..337] cell)) (NN:[338..344] factor)) (NP (-LRB-:[345..346] -LRB-) (NN:[346..349] SCF) (-RRB-:[349..350] -RRB-)))))))) (.:[350..351] .))) ;sentence 5 Span:352..553 ;Gene alteration of the c-kit extracellular domain was analysed by polymerase ;chain reaction-single strand conformation polymorphism (PCR-SSCP) in 25 ;patients with myeloproliferative disorders (MPD). ;[376..381]:gene-protein:"c-kit" ;[419..429]:gene-protein:"polymerase" ;[518..546]:malignancy-type:"myeloproliferative disorders" ;[548..551]:malignancy-type:"MPD" (SENT (S (NP-SBJ-1 (NP (NN:[352..356] Gene) (NN:[358..368] alteration)) (PP (IN:[369..371] of) (NP (DT:[372..375] the) (NN:[376..381] c-kit) (JJ:[382..395] extracellular) (NN:[396..402] domain)))) (VP (VBD:[403..406] was) (VP (VBN:[407..415] analysed) (NP-1 (-NONE-:[415..415] *)) (PP-MNR (IN:[416..418] by) (NP (NP (NML (NN:[419..429] polymerase) (NN:[430..435] chain) (NN:[437..445] reaction)) (HYPH:[445..446] -) (NML (NML (JJ:[446..452] single) (NN:[453..459] strand)) (NN:[460..472] conformation) (NN:[473..485] polymorphism))) (NP (-LRB-:[486..487] -LRB-) (NN:[487..495] PCR-SSCP) (-RRB-:[495..496] -RRB-)))) (PP-LOC (IN:[497..499] in) (NP (NP (CD:[500..502] 25) (NNS:[503..511] patients)) (PP (IN:[512..516] with) (NP (NP (JJ:[518..536] myeloproliferative) (NNS:[537..546] disorders)) (NP (-LRB-:[547..548] -LRB-) (NN:[548..551] MPD) (-RRB-:[551..552] -RRB-)))))))) (.:[552..553] .))) ;sentence 6 Span:554..758 ;In the N-terminal part of the domain, mobility shifts indicating sequence ;alteration were detected in three of the patients, two primary myelofibrosis ;(PMF) and one chronic myelogenous leukaemia (CML). ;[685..692]:malignancy-clinical-stage:"primary" ;[693..706]:malignancy-type:"myelofibrosis" ;[708..711]:malignancy-type:"PMF" ;[721..750]:malignancy-type:"chronic myelogenous leukaemia" ;[753..756]:malignancy-type:"CML" (SENT (S (PP (IN:[554..556] In) (NP (NP (DT:[557..560] the) (NML (NN:[561..562] N) (HYPH:[562..563] -) (JJ:[563..571] terminal)) (NN:[572..576] part)) (PP (IN:[577..579] of) (NP (DT:[580..583] the) (NN:[584..590] domain))))) (,:[590..591] ,) (NP-SBJ-1 (NP (NN:[593..601] mobility) (NNS:[602..608] shifts)) (VP (VBG:[609..619] indicating) (NP (NN:[620..628] sequence) (NN:[629..639] alteration)))) (VP (VBD:[640..644] were) (VP (VBN:[645..653] detected) (NP-1 (-NONE-:[653..653] *)) (PP-LOC (IN:[654..656] in) (NP (NP (NP (CD:[657..662] three)) (PP (IN:[663..665] of) (NP (DT:[666..669] the) (NNS:[671..679] patients)))) (,:[679..680] ,) (NP (NP (CD:[681..684] two) (NML (NML (JJ:[685..692] primary) (NN:[693..706] myelofibrosis)) (NML (-LRB-:[707..708] -LRB-) (NN:[708..711] PMF) (-RRB-:[711..712] -RRB-)))) (CC:[713..716] and) (NP (CD:[717..720] one) (NML (NML (JJ:[721..728] chronic) (JJ:[729..740] myelogenous) (NN:[741..750] leukaemia)) (NML (-LRB-:[752..753] -LRB-) (NN:[753..756] CML) (-RRB-:[756..757] -RRB-))))))))) (.:[757..758] .))) ;sentence 7 Span:759..876 ;The subsequent sequencing revealed the same point mutations at codon 52 ;causing amino acid substitution (Asp-->Asn). ;[803..818]:variation-type:"point mutations" ;[822..830]:variation-location:"codon 52" ;[840..863]:variation-type:"amino acid substitution" ;[865..868]:variation-state-original:"Asp" ;[871..874]:variation-state-altered:"Asn" (SENT (S (NP-SBJ (DT:[759..762] The) (JJ:[763..773] subsequent) (NN:[774..784] sequencing)) (VP (VBD:[785..793] revealed) (NP (DT:[794..797] the) (JJ:[798..802] same) (NN:[803..808] point) (NNS:[809..818] mutations)) (PP-LOC (IN:[819..821] at) (NP (NN:[822..827] codon) (CD:[828..830] 52))) (S-ADV (NP-SBJ (-NONE-:[830..830] *)) (VP (VBG:[832..839] causing) (NP (NML (JJ:[840..845] amino) (NN:[846..850] acid)) (NN:[851..863] substitution) (PRN (-LRB-:[864..865] -LRB-) (NP (NP (NN:[865..868] Asp)) (PP (SYM:[868..871] -->) (NP (NN:[871..874] Asn)))) (-RRB-:[874..875] -RRB-)))))) (.:[875..876] .))) ;sentence 8 Span:877..982 ;To our knowledge this is the first report with a c-kit point mutation found ;in human fresh tumour cells. ;[927..932]:gene-rna:"c-kit" ;[933..947]:variation-type:"point mutation" (SENT (S (PP (TO:[877..879] To) (NP (PRP$:[880..883] our) (NN:[884..893] knowledge))) (NP-SBJ (DT:[894..898] this)) (VP (VBZ:[899..901] is) (NP-PRD (NP (DT:[902..905] the) (JJ:[906..911] first) (NN:[913..919] report)) (PP (IN:[920..924] with) (NP (NP (DT:[925..926] a) (NN:[927..932] c-kit) (NN:[933..938] point) (NN:[939..947] mutation)) (VP (VBN:[948..953] found) (NP (-NONE-:[953..953] *)) (PP-LOC (IN:[954..956] in) (NP (JJ:[957..962] human) (JJ:[963..968] fresh) (NN:[969..975] tumour) (NNS:[976..981] cells)))))))) (.:[981..982] .))) ;section 9 Span:986..1030 ;PMID: 8555071 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[986..990] PMID) (::[990..991] :) (CD:[992..999] 8555071) (NN:[1000..1001] -LSB-) (NNP:[1001..1007] PubMed) (::[1008..1009] -) (NN:[1010..1017] indexed) (IN:[1018..1021] for) (NNP:[1022..1030] MEDLINE-RSB-)))